Cystic Fibrosis Foundation – Adding Tomorrows

The FDA recently approved Kalydeco, the first drug to address the underlying cause of cystic fibrosis for a small segment of the CF population. Meet an adult who is benefiting from this groundbreaking drug, and two children who are still in need of a lifesaving treatment for CF.

You might be interested in

LEAVE YOUR COMMENT

Your email address will not be published.